AstraZeneca’s AZN stock has taken a beating recently, with the company facing several pipeline setbacks in the past few months. AZN’s Recent Pipeline Setbacks In July, AstraZeneca announced the ...

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its ...

AstraZeneca (AZN) stock gains 0.63% after CEO purchases £7.26M in shares and EU recommends Klygefa approval for rare ...

AstraZeneca (AZN) stock edges up 0.63% as CEO buys 60,000 shares and the EU recommends Klygefa for myasthenia gravis ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AstraZeneca (AZN), the United Kingdom-headquartered Pharma giant, announced its Q1 2026 earnings today. Pre-market, the stock was down ~1%, priced at $185 per share, and AstraZeneca's market cap ...

AstraZeneca PLC (ISIN GB0009895292) stock traded lower on September 11, 2026 after the company announced that its Etcamah ...

AstraZeneca stock trades around $158 on the NYSE as the latest quarter delivers mid-single-digit revenue growth and solid net income, with analysts seeing more than 30 percent upside. AstraZeneca ...

Enhertu is a specifically engineered HER2-directed Dxd antibody-drug conjugate (ADC), discovered by Daiichi Sankyo and jointly developed and commercialised by AstraZeneca. It is already approved for ...